December 8, 2021 Non Regulatory InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod Read more
December 8, 2021 Non Regulatory InDex Pharmaceuticals inkluderar första patienten i PK-studien med cobitolimod Read more
November 24, 2021 Regulatory InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis Read more
November 24, 2021 Regulatory InDex Pharmaceuticals inkluderar första patienten i fas III-studien CONCLUDE med cobitolimod i ulcerös kolit Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2021 Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021 Read more
November 16, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada Read more
November 16, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i Kanada Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2022 Read more
November 9, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in the US Read more
November 9, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i USA Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2021 Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2021 Read more
August 24, 2021 Regulatory InDex Pharmaceuticals får FDA-godkännande att starta fas III-studien CONCLUDE med cobitolimod Read more
August 24, 2021 Regulatory InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals strengthens the clinical development organization in preparation of the start of the phase III study CONCLUDE with cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals stärker sin kliniska utvecklingsorganisation inför starten av fas III-studien CONCLUDE med cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod Read more